- Home
- BVS
BVS
Bioventus Inc.
as 07-26-2024 4:00pm EST
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 482.5M | IPO Year: | 2021 |
| Target Price: | $8.50 | AVG Volume (30 days): | 722.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.82 - $7.76 | Next Earning Date: | 08-06-2024 |
| Revenue: | $522,743,000 | Revenue Growth: | 1.72% |
| Revenue Growth (this year): | 7.03% | Revenue Growth (next year): | 5.85% |
Stock Insider Trading Activity of Bioventus Inc. (BVS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Singleton Mark Leonard | BVS | SVP & CFO | Jun 21 '24 | Sell | $5.57 | 9,219 | $51,349.83 | 84,895 | SEC Form 4 |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Jun 21 '24 | Sell | $5.57 | 2,559 | $14,253.63 | 41,199 | SEC Form 4 |
| Singleton Mark Leonard | BVS | SVP & CFO | Jun 17 '24 | Sell | $5.84 | 13,753 | $80,317.52 | 63,114 | SEC Form 4 |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Jun 17 '24 | Sell | $5.84 | 8,759 | $51,152.56 | 35,158 | SEC Form 4 |
| Singleton Mark Leonard | BVS | SVP & CFO | Apr 11 '24 | Sell | $4.75 | 4,000 | $19,000.00 | 34,665 | SEC Form 4 |
| D'Adamio Anthony | BVS | SVP & General Counsel | Apr 11 '24 | Sell | $4.75 | 3,054 | $14,506.50 | 58,242 | SEC Form 4 |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Apr 11 '24 | Sell | $4.75 | 1,325 | $6,293.75 | 17,042 | SEC Form 4 |
| Singleton Mark Leonard | BVS | SVP & CFO | Mar 21 '24 | Sell | $5.39 | 5,541 | $29,852.69 | 25,665 | SEC Form 4 |
| D'Adamio Anthony | BVS | SVP & General Counsel | Mar 15 '24 | Sell | $5.46 | 3,125 | $17,062.50 | 51,371 | SEC Form 4 |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Mar 15 '24 | Sell | $5.46 | 1,217 | $6,644.82 | 14,067 | SEC Form 4 |
Latest Bioventus Inc. News
BVS Breaking Stock News: Dive into BVS Ticker-Specific Updates for Smart Investing
Zacks
24 days ago
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
2 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
2 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
2 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St.
2 months ago
Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
Simply Wall St.
2 months ago
Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Compare BVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BVS Bioventus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.